文献速递临床免疫临床微生物

bioMérieux分离型Vidas莱姆IgM II和IgG II作为一线诊断试剂的评估

Evaluation of bioMérieux's Dissociated Vidas Lyme IgM II and IgG II as a First-Tier Diagnostic Assay for Lyme Disease.
PubMed 文献 · J Clin Microbiol · 2017-03-22

该研究以471例特征明确的莱姆病患者和对照样本,评估bioMérieux分离型Vidas莱姆IgM II(LYM)和IgG II(LYG)酶免疫分析(EIA)作为一线检测的性能。与联合Vidas检测(LYT)相比,作为一线检测时敏感性83%至85%、特异性85%至88%,观察一致率80%;改良两层级检测(MTTT)敏感性显著高于标准两层级检测(STTT)。总体上LYM/LYG与LYT性能相当。

要点

  • 分离型LYM/LYG作为一线检测与联合LYT敏感性83%至85%、特异性85%至88%相似。
  • LYM/LYG用于MTTT时敏感性76%至77%、特异性98%至99%,高于STTT。
  • MTTT策略的敏感性显著高于STTT。

核心结论

  • 分离型LYM/LYG EIA在逐项比较或作为STTT/MTTT一线检测时,总体性能与联合LYT EIA相当,仅有少数例外。

研究设计与样本

  • 采用471例特征明确的莱姆病患者和对照样本,评估分离型LYM/LYG EIA与联合LYT EIA作为一线检测及用于两层检测算法的性能。

主要发现

  • 作为一线检测时,LYT与LYM/LYG的敏感性为83%至85%,特异性为85%至88%,观察一致率为80%。
  • LYM/LYG策略后接Western免疫印迹时敏感性为68%至69%、特异性为97%;用于MTTT时敏感性为76%至77%、特异性为98%至99%。
  • MTTT策略的敏感性显著高于STTT。

关键数值与推荐

  • 一线检测:敏感性83%至85%,特异性85%至88%(LYT与LYM/LYG)。
  • 后接Western免疫印迹:敏感性68%至69%,特异性97%。
  • MTTT:敏感性76%至77%,特异性98%至99%。
  • 观察一致率80%。

临床怎么用

  • 分离型LYM/LYG EIA可作为莱姆病一线检测的等效替代选项。
  • 采用MTTT策略可较STTT获得显著更高的敏感性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The recommended laboratory diagnostic approach for Lyme disease is a standard two-tiered testing (STTT) algorithm where the first tier is typically an enzyme immunoassay (EIA) that if positive or equivocal is reflexed to Western immunoblotting as the second tier. bioMérieux manufactures one of the most commonly used first-tier EIAs in the United States, the combined IgM/IgG Vidas test (LYT). Recently, bioMérieux launched its dissociated first-tier tests, the Vidas Lyme IgM II (LYM) and IgG II (LYG) EIAs, which use purified recombinant test antigens and a different algorithm than STTT. The dissociated LYM/LYG EIAs were evaluated against the combined LYT EIA using samples from 471 well-characterized Lyme patients and controls. Statistical analyses were conducted to assess the performance of these EIAs as first-tier tests and when used in two-tiered algorithms, including a modified two-tiered testing (MTTT) approach where the second-tier test was a C6 EIA. Similar sensitivities and specificities were obtained for the two testing strategies (LYT versus LYM/LYG) when used as first-tier tests (sensitivity, 83 to 85%; specificity, 85 to 88%) with an observed agreement of 80%. Sensitivities of 68 to 69% and 76 to 77% and specificities of 97% and 98 to 99% resulted when the two EIA strategies were followed by Western immunoblotting and when used in an MTTT, respectively. The MTTT approach resulted in significantly higher sensitivities than did STTT. Overall, the LYM/LYG EIAs performed equivalently to the LYT EIA in test-to-test comparisons or as first-tier assays in STTT or MTTT with few exceptions.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Molins CR, Delorey MJ, Replogle A, et al. Evaluation of bioMérieux's Dissociated Vidas Lyme IgM II and IgG II as a First-Tier Diagnostic Assay for Lyme Disease. J Clin Microbiol. 2017. PMID: 28330884. doi:10.1128/JCM.02407-16

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。